SerbiaTuberculosis profile
Population  2016 8.8 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.084 (0.073–0.096) 0.96 (0.83–1.1)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.02 (0.01–0.03)
Incidence  (includes HIV+TB) 1.7 (1.4–2) 19 (16–22)
Incidence (HIV+TB only) 0.01 (<0.01–0.014) 0.11 (0.07–0.16)
Incidence (MDR/RR-TB)** 0.027 (0.013–0.041) 0.3 (0.15–0.46)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.072 (0.061–0.083) 0.67 (0.57–0.77) 0.74 (0.63–0.85)
Males 0.081 (0.069–0.093) 0.87 (0.74–1) 0.95 (0.81–1.1)
Total 0.15 (0.13–0.18) 1.5 (1.3–1.8) 1.7 (1.4–2)
TB case notifications, 2016  
Total cases notified 1 488
Total new and relapse 1 472
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 6%
          - % pulmonary 82%
          - % bacteriologically confirmed among pulmonary 68%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.05 (0.04–0.06)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 5 6%
          - on antiretroviral therapy 5 100%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  19
(8–29)
Estimated % of TB cases with MDR/RR-TB 1.1% (0.49–2.2) 4.7% (1.3–11)  
% notified tested for rifampicin resistance      
MDR/RR-TB cases tested for resistance to second-line drugs   6
Laboratory-confirmed cases MDR/RR-TB: 8, XDR-TB: 1
Patients started on treatment **** MDR/RR-TB: 10, XDR-TB: 1
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 89% 1 647
Previously treated cases, excluding relapse, registered in 2015 59% 22
HIV-positive TB cases registered in 2015 50% 4
MDR/RR-TB cases started on second-line treatment in 2014 54% 13
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions) 8.2
Funding source: 98% domestic, 0% international, 2% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-17 Data: www.who.int/tb/data